Information Provided By:
Fly News Breaks for December 24, 2015
RVNC
Dec 24, 2015 | 08:29 EDT
Cowen said Revance's RT001 trial data showed mixed results for hyperhidrosis but provided proof-of-concept as a favorable treatment effect. The firm said RT001 is the first neurotoxin to show an increased duration of effect versus Botox and believes it could become a transformational, $1B product. Cowen reiterated its Outperform rating and $55 price target on Revance shares.
News For RVNC From the Last 2 Days
There are no results for your query RVNC